Therefore, this study reveals a novel mechanism by which MUC1‐PP2A awakes CSLC expansion via switching symmetric division, suggesting a potential therapeutic strategy for MUC1‐positive SCLC. This evidence concerns the gene PTPA and small cell lung carcinoma.